HER2-positive Breast Cancer Registry

计划入组 1,000 人 · 首次发布于 2024 年 9 月 19 日

Thero2-01S22 in HER2-positive Breast Cancer

计划入组 320 人 · 首次发布于 2023 年 1 月 26 日

TME Alteration in HER2 Positive Breast Cancer

计划入组 30 人 · 首次发布于 2024 年 8 月 1 日

HER2+ Breast Cancer(Diakonos)

Margetuximab(Margenza)

Rx

Pertuzumab(Perjeta, Perjeta-Herceptin, Phesgo)

Arvinas

United States

JAPAN BREAST CANCER RESEARCH GROUP

Japan

ANZ BREAST CANCER TRIALS GROUP LIMITED

Australia

Repurposed Cancer Drug Shows Promise in Treating HER2-Positive Breast Cancer

Trastuzumab Deruxtecan Shows Efficacy in HER2-Positive Breast Cancer Brain Metastases

Russia's Biocad Initiates Phase III Trial of Kadcyla Biosimilar BCD-237 for HER2-Positive Breast Cancer